Tarek Nafee, MD
Interventional Cardiology · Royal Oak, MINPI 1730740838
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,402 of the $2,691 with a category attached, or 89.3%. It is spread thinly across 20 manufacturers, the largest accounting for just 19.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,175, 2.6 times the $454 reported in 2019. That places this record below the midpoint for interventional cardiology clinicians in MI, where the typical reported total is $6,857.
Across 52 payments — averaging $51.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$529
- Boston Scientific$410
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$338
- Abiomed$211
- Cook Incorporated$200
- Pfizer$140
- plus $863 from 14 others
What the payments were for
- Grants$2007%
- Food & beverage$2,40289%
- Education$893%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 9 | $529 |
| Boston Scientific | 9 | $410 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $338 |
| Abiomed | 3 | $211 |
| Cook Incorporated | 1 | $200 |
| Pfizer | 2 | $140 |
| Inari Medical, Inc. | 1 | $137 |
| Radius Health, Inc. | 1 | $125 |
| Cvrx, Inc. | 1 | $100 |
| Insmed, Inc. | 1 | $89 |
| Johnson & Johnson(2 entities) | 5 | $82 |
| E.r. Squibb & Sons, L.L.C. | 2 | $57 |
| AstraZeneca | 2 | $53 |
| Cook Medical LLC | 1 | $53 |
| Novo Nordisk | 1 | $50 |
| Angiodynamics, Inc. | 1 | $43 |
| Getinge USA Sales, LLC | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Gilead | 1 | $15 |
| Merck | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AVVIGO Guidance System$293
- OPTIS$190
- Impella$140
- FlowTriever$137
- ClotTriever$137
- Tymlos$125
- ELIQUIS$120
- Barostim Neo System$100
- LifeVest$100
How this compares
$2,691 in reported general payments places this provider in the 25th percentile of 187 interventional cardiology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 12 | $21,900 |
| Atorvastatin Calcium | 24 | $220 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Royal Oak
- Ryan MadderRoyal Oak$231K
- Lakshmi RaoRoyal Oak$26K
- Amir KakiDetroit$1.8M
- Tamam MohamadDetroit$960K
- Paul GrossmanAnn Arbor$630K
- Jason RicciPetoskey$594K
- Tim FischellKalamazoo$468K
- Mir BasirDetroit$442K
- Amr AbbasBerkley$416K
- Safwan KassasSaginaw$340K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.